Innovassynth Technologies (India) Ltd reported a net loss of Rs 28.79 crore for FY26 as it integrated operations following its merger. While total income saw a modest rise to Rs 102.96 crore, higher operating and employee costs weighed on the bottom line. The company also completed a post-year-end Rights Issue to bolster capital. Investors should focus on management's ability to drive operational efficiency and cost control as the entity moves past this transition phase.
Innovassynth Technologies FY26 Results and Merger Update
Total Income reached Rs 102.96 crore for the financial year ended March 31, 2026.
Net loss stood at Rs 28.79 crore compared to a profit of Rs 20.15 crore in the prior period.
Reader Takeaway: Revenue grew during the transition, but higher integration costs resulted in a loss; operational efficiency is critical.
What just happened
Innovassynth Technologies has released its financial performance for the fiscal year ended March 31, 2026. The results reflect the company's first full annual report following the merger by absorption of the erstwhile Innovassynth Technologies (India) Limited with Innovassynth Investments Limited, which became effective on December 19, 2025. Consequently, the company recorded a net loss of Rs 28.79 crore. Revenue was reported at Rs 102.96 crore.
Why this matters
The financial shift from profit to loss highlights the substantial expenses associated with the merger and the subsequent integration of the two entities. As a CRDMO and specialty chemicals player, the company is currently in a foundation-building phase. The market will be watching to see how quickly the firm can return to profitability as it leverages its 250+ KL reaction capacity and 24,000 sq. ft. R&D infrastructure.
What changes now
Post-merger, the company has undergone significant capital restructuring. It allotted over 4.74 crore equity shares to shareholders of the transferor company. Furthermore, in May 2026, the company successfully executed a Rights Issue, raising approximately Rs 69.65 crore at an issue price of Rs 40 per share to strengthen its balance sheet.
Risks to watch
Profitability remains the primary concern as high operating, employee, and depreciation costs impacted the latest results. Additionally, investors should note a contingent liability of Rs 0.60 crore related to a customs department demand, which remains subject to legal outcomes. The company's future performance hinges on the successful scaling of its life sciences and specialty chemicals operations.
Context metrics
The current financial data reflects a transitional period. Notably, previous year figures (FY24-25) were restated as they represented a six-month window. The company continues to maintain its EcoVadis Gold Sustainability Rating, a factor that may support its positioning with over 100 global customers.